Mode
Text Size
Log in / Sign up
N/A Completed N=4,105

Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)

Primary Hypercholesterolemia · Homozygous Familial Hypercholesterolemia
Source: ClinicalTrials.gov NCT00704535 ↗
Enrolled (actual)
4,105
Serious AEs
0.1%
Results posted
Jul 2009
Primary outcomePrimary: Safety as Measured by Number of Subjects With at Least One Adverse Event — 45 subjects

Summary

The purpose of this study is to evaluate the overall safety, tolerability, and efficacy of Ezetimibe when used alone or in combination with a statin in patients with hypercholesterolemia

Outcome Measures

OutcomeResultp-value
PRIMARY
Safety as Measured by Number of Subjects With at Least One Adverse Event
45 —
PRIMARY
Safety as Measured by Number and Type of Adverse Events.
2; 4; 1; 3; 1; 6 —
PRIMARY
Safety as Measured by Severity of Adverse Events as Determined by the Investigator
49; 4; 1 —
PRIMARY
Safety as Measured by Adverse Event Relatedness to Study Drug as Reported by the Investigator.
20; 8; 26 —
PRIMARY
Safety as Measured by Dose Adjustment Upon Incidence of an Adverse Event
45; 6; 3 —
PRIMARY
Safety as Measured by Outcome of Adverse Events
49; 2; 3 —
PRIMARY
Tolerability as Measured by Subject Self-assessment
1325; 1956; 713; 54; 3; 54 —
SECONDARY
To Evaluate the Efficacy of Ezetimibe in Lowering Serum Cholesterol Levels 28 Days After Visit 1 (Baseline)
-62.70 —

Eligibility Criteria

Inclusion Criteria

  • Outpatient men or women, age 18 years and above.
  • Patients with primary (heterozygous familial and non-familial) hypercholesterolemia or homozygous familial hypercholesterolemia.

Exclusion Criteria

  • Known hypersensitivity to Ezetimibe.
  • Moderate to severe hepatic insufficiency.
  • Persistent elevation of serum transaminase levels of more than 1.5 times the upper limit of normal.
  • Pregnancy or lactation.
  • Concomitant intake of bile acid sequestrants (resins), nicotinic acid (niacin), fibric acid (fibrates), or cyclosporine
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00704535). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search